An Overview of Adalimumab Biosimilars
Clinicians and a pharmacist provide an overview of the emerging adalimumab biosimilars in the recent years.
EP: 1.The Need for Biosimilars in Inflammatory Diseases and Regulatory Requirements for Approval
EP: 2.An Overview of Adalimumab Biosimilars
EP: 3.The Pharmacological Aspects of Adalimumab Biosimilars
EP: 4.The Safety and Efficacy of Adalimumab Biosimilars in Inflammatory Diseases
EP: 5.Impact of the Launch of Adalimumab Biosimilars in Different Clinical and Pharmacy Settings
EP: 6.The Role of Pharmacy Benefit Managers and Payers in Accessing Adalimumab Biosimilars
EP: 7.Strategies to Increase Adalimumab Biosimilar Uptake in Clinical Practice
EP: 8.Selecting Between Adalimumab Biosimilars for Your Patients
This is a video synopsis/summary of a panel discussion involving Jamie T. Brogan, MSN, APRN, FNP-BC; Kostas Botsoglou, MD; Jordan Axelrad, MD, MPH; Sophia Humphreys, PharmD, MHA; and Peter Lio, MD.
The discussion focuses on adalimumab biosimilars, examining their indications, mechanism of action, interchangeability, and clinical implications. Currently, there are over 40 biosimilars created for a dozen biologic products, with a focus on adalimumab. While most indications of adalimumab have biosimilar alternatives, three orphan drug indications remain unapproved for biosimilars.
The mechanism of action for adalimumab biosimilars mirrors that of the reference product, with rigorous FDA review processes ensuring structural and functional similarity. Biosimilars must demonstrate identical primary and secondary structures to reference products, differing only in tertiary and quaternary folding. Additionally, they share the same administration route and strength.
Interchangeability designation by the FDA streamlines pharmacy-level switches, but specific conditions must be met. Biosimilars must replicate clinical outcomes, maintain safety profiles, and undergo switching studies. Despite potential benefits, providers emphasize the importance of patient education and notification regarding biosimilar switches to maintain therapy continuity.
The discussion highlights the need for proactive patient communication and regulatory compliance to facilitate smooth transitions between reference and biosimilar products. Clinicians express willingness to embrace interchangeable biosimilars to reduce administrative burdens and ensure uninterrupted patient care, underscoring the importance of effective communication and documentation within healthcare systems.
Video synopsis is AI-generated and reviewed by HCPLive editorial staff.
